E
7.59
0.18 (2.36%)
| Penutupan Terdahulu | 7.41 |
| Buka | 7.36 |
| Jumlah Dagangan | 467,048 |
| Purata Dagangan (3B) | 1,246,056 |
| Modal Pasaran | 507,226,432 |
| Harga / Buku (P/B) | 2.69 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Sep 2025 - 25 Sep 2025 |
| EPS Cair (TTM) | -1.63 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 11.16% |
| Nisbah Semasa (MRQ) | 12.66 |
| Aliran Tunai Operasi (OCF TTM) | -75.39 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -47.37 M |
| Pulangan Atas Aset (ROA TTM) | -20.35% |
| Pulangan Atas Ekuiti (ROE TTM) | -33.97% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | enGene Holdings Inc. | Menurun | Menurun |
AISkor Stockmoo
0.6
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.63 |
|
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 13.63% |
| % Dimiliki oleh Institusi | 77.57% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 33.00 (Oppenheimer, 335.07%) | Beli |
| Median | 21.00 (176.86%) | |
| Rendah | 10.00 (UBS, 31.84%) | Pegang |
| Purata | 21.60 (184.77%) | |
| Jumlah | 4 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 8.09 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Citizens | 12 Nov 2025 | 21.00 (176.86%) | Beli | 8.68 |
| Morgan Stanley | 12 Nov 2025 | 19.00 (150.49%) | Beli | 8.68 |
| 12 Sep 2025 | 18.00 (137.31%) | Beli | 5.71 | |
| Oppenheimer | 12 Nov 2025 | 33.00 (335.07%) | Beli | 8.68 |
| UBS | 12 Nov 2025 | 10.00 (31.84%) | Pegang | 8.68 |
| HC Wainwright & Co. | 12 Sep 2025 | 25.00 (229.60%) | Beli | 5.71 |
| 08 Sep 2025 | 25.00 (229.60%) | Beli | 5.43 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 02 Dec 2025 | Pengumuman | enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness |
| 25 Nov 2025 | Pengumuman | enGene to Present at the Piper Sandler 37th Annual Healthcare Conference |
| 13 Nov 2025 | Pengumuman | enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants |
| 12 Nov 2025 | Pengumuman | enGene Announces Proposed Public Offering of Common Shares |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |